Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Renal response of selinexor,  bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

Huixing Zhou, Long Chang, Jie Ma et al. Nov 03, 2025 pp. 5830-5830 10.1182/blood-2025-5830

Abstract Renal impairment (RI) is a common complication of multiple myeloma (MM), accounting for ~40% of newly diagnosed MM (NDMM), which as...

Abbreviated anticoagulation regimen with direct oral anticoagulants is safe and efficacious in the management of infection-associated cerebral sinovenous thrombosis in children

Sriveda Boyalakuntla, Agnieszka Kielian, Eva Robinson et al. Nov 03, 2025 pp. 4907-4907 10.1182/blood-2025-4907

Abstract Introduction There has been a dramatic increase in the rate of venous thrombo-embolism (VTE) amongst hospitalized children in the U...

Liquid biopsy by analysis of circulating tumor cells, hormonal and inflammatory biomarkers in plasma cell neoplasms, at Fundación Santa Fe de Bogotá hospital

Martha Romero Prieto, Mateo Mejia Saldarriaga, Juanita Zuluaga Castro et al. Nov 03, 2025 pp. 4009-4009 10.1182/blood-2025-4009

Abstract The detection of circulating tumor cells (CTC) is becoming increasingly important due to growing evidence demonstrating their progn...

Clonal evolution and therapeutic vulnerabilities in SETBP1-mutated leukemia: Insights from physiological mouse model and integrative functional screens

Wataru Saika, Koutarou Nishimura, Atsushi Tanaka et al. Nov 03, 2025 pp. 989-989 10.1182/blood-2025-989

Abstract Somatic mutations in SET binding protein 1 (SETBP1), a putative chromatin regulator, occur in ~30% of high-risk myeloid malignancie...

Single-center experience with emicizumab in Chinese children under 3 years with severe Hemophilia A

Qing Yan, Shaoyan Hu, Jingfang Hu et al. Nov 03, 2025 pp. 6616-6616 10.1182/blood-2025-6616

Abstract Background: Prophylactic treatment is essential for children with severe hemophilia A to prevent bleeding episodes and long-term jo...

Total marrow irradiation-based, intensified reduced-intensity conditioning regimen for haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide: A prospective study

Leonardo Arcuri, Mariana Kerbauy, Lucila Kerbauy et al. Nov 03, 2025 pp. 7738-7738 10.1182/blood-2025-7738

Abstract Introduction Post-transplant cyclophosphamide (PTCy) has nearly revolutionized the field of haploidentical hema...

Association of low annexin A2 levels with venous thromboembolism in sickle cell anemia: A potential biomarker

Ugochi Ogu, Athena Starlard-Davenport, Alana Smith et al. Nov 03, 2025 pp. 4721-4721 10.1182/blood-2025-4721

Abstract Introduction Sickle cell disease (SCD) is an inherited blood disorder that affects millions of individuals worldwide. It is referre...

Efficacy of a 14-day venetoclax regimen in combination with a hypomethylating agent for Acute Myeloid Leukemia: A single-center retrospective analysis

Johnathan Fraebel, Aaron Pathak, Eiline Cai et al. Nov 03, 2025 pp. 6994-6994 10.1182/blood-2025-6994

Abstract Background : Venetoclax in combination with a hypomethylating agent has become the current standard of care in elderly or unfit pat...

Absolute lymphocyte count is predictive of response to salvage therapies for post-CAR T failure

Hazim Ababneh, Andrea Ng, Matthew Frigault et al. Nov 03, 2025 pp. 1928-1928 10.1182/blood-2025-1928

Abstract Introduction: Most patients with relapsed or refractory large B-cell lymphoma who undergo CD19-directed CAR T-c...

Recruitment strategies and enrollment for an ongoing virtually supervised prehabilitation exercise intervention in patients diagnosed with multiple myeloma scheduled to receive autologous stem cell transplant: Preliminary findings

Amber Normann, Rebekah Wilson, Christina Dieli-Conwright Nov 03, 2025 pp. 6374-6374 10.1182/blood-2025-6374

Abstract Background: Exercise interventions remain understudied in the prehabilitation setting for patients with hematologic malignancies wi...

Efficacy of tgrx-678, a potent BCR::ABL1 allosteric inhibitor, in CML-CP and CML-AP patients harboring T315I mutation: Results from a phase 1 study

Qian Jiang, WeiMing Li, Yanli Zhang et al. Nov 03, 2025 pp. 902-902 10.1182/blood-2025-902

Abstract Background: TGRX-678 is a novel allosteric inhibitor of ABL kinases that specifically targets the Myristoyl Pocket (STAMP) of ABL....

Single-cell DNA profiling unveils clonal evolution and identifies mechanisms of therapeutic resistance and progression in monoclonal gammopathies

Beñat Ariceta, Paula Aguirre-Ruiz, Andrea Castro et al. Nov 03, 2025 pp. 7445-7445 10.1182/blood-2025-7445

Abstract INTRODUCTION Monoclonal gammopathies –including MGUS, smoldering multiple myeloma (SMM), and multiple myeloma (MM)– are driven by c...

Protein levels of isocitrate dehydrogenase 1 and 2 are prognostic and independent of mutation status in acute myelogenous leukemia

Eduardo de Camargo Magalhaes, Samanta Catueno, Brandon Brown et al. Nov 03, 2025 pp. 5270-5270 10.1182/blood-2025-5270

Abstract INTRODUCTION: Mutations in the Isocitrate Dehydrogenase 1 and 2 (IDH1/2) occur in ~20% of Acute Myelogenous Leukemia (AML) cases an...

Post-induction minimal residual disease assessment by flow cytometry and molecular biology enables prognostic stratification of patients with NPM1-mutated Acute Myeloid Leukemia: A dataml registry study.

Jean Philippe Vial, Inès Vergnolle, Laetitia Largeaud et al. Nov 03, 2025 pp. 1744-1744 10.1182/blood-2025-1744

Abstract IntroductionMRD assessment in AML provides a quantitative approach to define a deeper remission status and refine the risk assessme...

Deep hematologic response to daratumumab without cardiac recovery in AL amyloidosis: A persistent dissociation in real-world practice

Belkacem Mansour, Mohamed Keita, Abdallah MAAKAROUN Nov 03, 2025 pp. 7505-7505 10.1182/blood-2025-7505

Abstract Background Daratumumab has transformed the management of AL amyloidosis by significantly improving hematologic response rates [1]....

Prognostic impact of persistent and treatment-emergent cytopenia in 879 myelofibrosis patients treated with ruxolitinib: The “RUX-MF” study

Francesca Palandri, Filippo Branzanti, Massimiliano Bonifacio et al. Nov 03, 2025 pp. 3806-3806 10.1182/blood-2025-3806

Abstract Introduction Cytopenia, such as anemia and thrombocytopenia, are associated with inferior overall survival (OS) in patients (pts) wi...

Efficacy and safety of zanubrutinib combined with reduced-dose bendamustine and Rituximab for eldly Mantle Cell Lymphoma: A retrospective analysis

Ping Yang, Shuozi Liu, Chuanyuan Li et al. Nov 03, 2025 pp. 7097-7097 10.1182/blood-2025-7097

Abstract BR regimen was a common treatment for elderly patients with mantle cell lymphoma, however, infection and treatment tolerability rem...

Therapy-related core binding factor Acute Myeloid Leukemia – a Study of the french acute leukemia intergroup

Mathilde Chanut, Loïc Vasseur, Matthieu Duchmann et al. Nov 03, 2025 pp. 37-37 10.1182/blood-2025-37

Abstract Introduction Therapy-related CBF-AMLs represent approximately 10% of all CBF-AMLs and are associated with poorer outcomes, partly d...

Preliminary analysis of a single-center study on chidamide combined with ICD regimen in bortezomib-exposed relapsed/refractory multiple myeloma patients

Zhenshu Xu, Ping Weng, Shujuan Xu et al. Nov 03, 2025 pp. 7592-7592 10.1182/blood-2025-7592

Abstract Background: The therapeutic challenge in relapsed/refractory multiple myeloma (RRMM) stems from high genomic instability, clonal he...

Haplo-identical transplantation in patients with myelofibrosis, a phase 2 prospective multicentric study

Marie Robin, Michael Loschi, Marie-Thérèse Rubio et al. Nov 03, 2025 pp. 506-506 10.1182/blood-2025-506

Abstract In higher risk myelofibrosis patients, the only treatment able to improve survival and cure the disease is allogeneic hematopoietic...

Peripheral immune checkpoints predict prognosis and reveal PD-1/treg/IL-10 crosstalk in B cell lymphoma

Bing Pan, Sijia Li, Ruixin Zheng et al. Nov 03, 2025 pp. 7088-7088 10.1182/blood-2025-7088

Abstract Background: B-cell lymphoma is a hematologic malignancy associated with B cell molecular pathways and immune microenvironment dysre...

Butyrate ameliorates Tet2-deficient clonal hematopoiesis phenotypes driven by high B12-induced gut dysbiosis.

John Brabson, Peter Lyon, Tiffany Leesang et al. Nov 03, 2025 pp. 3173-3173 10.1182/blood-2025-3173

Abstract Introduction: Recent studies have linked elevated vitamin B12 serum levels with the presence of clonal hematopoiesis (CH) and an in...

Red cell indices in adolescents with iron deficiency and heavy menstrual bleeding

Lam Duc, Kristina Haley Nov 03, 2025 pp. 2621-2621 10.1182/blood-2025-2621

Abstract Background: Iron deficiency (ID) and iron deficiency anemia (IDA) are common in adolescents with heavy menstrua...

Epigenetic dysregulation of the polycomb axis in Acute Myeloid Leukemia: Clinical and prognostic correlates

Ameed Bawwab, Emily Zabor, Moath Albliwi et al. Nov 03, 2025 pp. 7035-7035 10.1182/blood-2025-7035

Abstract Background Epigenetic regulation of gene expression is a complex biological process. Polycomb Repressive Complex (PCR) 1 & 2 re...

VISTA contributes to disease progression in high-risk myelodysplastic syndrome

Raymond Zhang, Hyundong Yoon, Qianni Hu et al. Nov 03, 2025 pp. 673-673 10.1182/blood-2025-673

Abstract Myelodysplastic syndrome (MDS) is a hematologic disorder characterized by ineffective hematopoiesis and cytopenias, with a risk of...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page